Adalta Ltd
ASX:1AD

Watchlist Manager
Adalta Ltd Logo
Adalta Ltd
ASX:1AD
Watchlist
Price: 0.005 AUD -16.67% Market Closed
Market Cap: AU$11.5m

Operating Margin

-638.7%
Current
Declining
by 329.8%
vs 3-y average of -308.9%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-638.7%
=
Operating Income
AU$-4.4m
/
Revenue
AU$695.7k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-638.7%
=
Operating Income
AU$-4.4m
/
Revenue
AU$695.7k

Peer Comparison

Country Company Market Cap Operating
Margin
AU
Adalta Ltd
ASX:1AD
11.5m AUD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 71% of companies in Australia
Percentile
29th
Based on 3 951 companies
29th percentile
-638.7%
Low
-14 949 200% — -526.4%
Typical Range
-526.4% — 6.1%
High
6.1% — 145 596.9%
Distribution Statistics
Australia
Min -14 949 200%
30th Percentile -526.4%
Median -25.2%
70th Percentile 6.1%
Max 145 596.9%

Adalta Ltd
Glance View

Market Cap
11.5m AUD
Industry
Biotechnology

AdAlta Ltd. operates as a biotechnology company, discovers, develops, and commercializes protein based therapeutics. The company is headquartered in Melbourne, Victoria. The company went IPO on 2016-08-22. The firm is focused on using its technology platform to generate protein therapeutics, known as i-bodies, for treating a range of human diseases. The Company’s lead candidate AD-214 is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases. AD-214 is an Fc-Fusion protein that contains two AD-114 i-body molecules at the front end, that bind with high affinity to the human target. The i-body has also demonstrated its usefulness in treating fibrosis of the eye and is being pursued as an additional opportunity for the treatment of age-related macular degeneration (wet-AMD). The i-body is identified to have affinity and specificity with a drug target of interest, its effectiveness is evaluated in cell-based assays (in vitro) and in animal experiments (in vivo).

1AD Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-638.7%
=
Operating Income
AU$-4.4m
/
Revenue
AU$695.7k
What is Adalta Ltd's current Operating Margin?

The current Operating Margin for Adalta Ltd is -638.7%, which is below its 3-year median of -308.9%.

How has Operating Margin changed over time?

Over the last 3 years, Adalta Ltd’s Operating Margin has decreased from -217.7% to -638.7%. During this period, it reached a low of -638.7% on Jul 30, 2025 and a high of -136.2% on Jun 30, 2023.

Back to Top